Evidence map›Paper›PMID 37753732›Full record

ArticleMolecular oncology2024

Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapy.

Goran Rac, Hiten D Patel, Christopher James, Shalin Desai, Vincent M Caruso, Daniel S Fischer, Peter S Lentz, Ceressa T Ward, Brian C Mazzarella, Kevin G Phillips and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Goran RacDepartment of Urology, Loyola University Medical Center, Maywood, IL, USA.ORCID 0000-0003-4694-1634
Hiten D PatelDepartment of Urology, Loyola University Medical Center, Maywood, IL, USA.
Christopher JamesDepartment of Urology, Loyola University Medical Center, Maywood, IL, USA.
Shalin DesaiDepartment of Urology, Loyola University Medical Center, Maywood, IL, USA.
Vincent M CarusoConvergent Genomics, Inc., South San Francisco, CA, USA.
Daniel S FischerConvergent Genomics, Inc., South San Francisco, CA, USA.
Peter S LentzConvergent Genomics, Inc., South San Francisco, CA, USA.
Ceressa T WardConvergent Genomics, Inc., South San Francisco, CA, USA.
Brian C MazzarellaConvergent Genomics, Inc., South San Francisco, CA, USA.
Kevin G PhillipsConvergent Genomics, Inc., South San Francisco, CA, USA.
Chirag DoshiDepartment of Urology, Loyola University Medical Center, Maywood, IL, USA.
Vincent T BicoccaConvergent Genomics, Inc., South San Francisco, CA, USA.ORCID 0000-0002-5702-4586
Trevor G LevinConvergent Genomics, Inc., South San Francisco, CA, USA.
Alan J WolfeDepartment of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA.ORCID 0000-0003-4532-0545
Gopal N GuptaDepartment of Urology, Loyola University Medical Center, Maywood, IL, USA.ORCID 0000-0002-8502-708X

Funding

SBIR grant application to develop and commercialize a urine based medical diagnostic for the detection of bladder cancer recurrence.R44CA200174 · NCI · CONVERGENT GENOMICS, INC. · PI LEVIN, TREVOR · 2016 to 2021
$6.2M
NCI NIH HHS R44 CA200174
6 · The paper itself

Abstract

Intravesical therapy (IVT) is the standard of care to decrease risk of recurrence and progression for high-grade nonmuscle-invasive bladder cancer. However, post-IVT recurrence remains common and the ability to risk-stratify patients before or after IVT is limited. In this prospectively designed and accrued cohort study, we examine the utility of urinary comprehensive genomic profiling (uCGP) for predicting recurrence risk following transurethral resection of bladder tumor (TURBT) and evaluating longitudinal IVT response. Urine was collected before and after IVT instillation and uCGP testing was done using the UroAmp™ platform. Baseline uCGP following TURBT identified patients with high (61%) and low (39%) recurrence risk. At 24 months, recurrence-free survival (RFS) was 100% for low-risk and 45% for high-risk patients with a hazard ratio (HR) of 9.3. Longitudinal uCGP classified patients as minimal residual disease (MRD) Negative, IVT Responder, or IVT Refractory with 24-month RFS of 100%, 50%, and 32%, respectively. Compared with MRD Negative patients, IVT Refractory patients had a HR of 10.5. Collectively, uCGP enables noninvasive risk assessment of patients following TURBT and induction IVT. uCGP could inform surveillance cystoscopy schedules and identify high-risk patients in need of additional therapy.

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsAdministration, IntravesicalCohort StudiesGenomicsHumansNeoplasm InvasivenessNeoplasm Recurrence, LocalRetrospective StudiesBacillus Calmette-Guérinbladder cancergenomicsintravesical instillationpersonalized medicinerisk assessment

Identifiers

PMID37753732
PMCPMC10850796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.